Originally published by our sister publication Clinical Oncology News
In an ongoing phase 3 trial, rusfertide (Takeda/Protagonist Therapeutics), a first-in-class hepcidin mimetic, reduced symptoms and the need for phlebotomy in patients with polycythemia vera (PV), a hematologic malignancy that is associated with overproduction of red blood cells.
The first PV drug therapy targeted at regulating red cell production, rusfertide “has the potential to become part of the standard-of-care